Dual hormonal replacement with insulin and recombinant human insulin- like growth factor I in IDDM: Effects on glycemic control, IGF-I levels, and safety profile

Diabetes Care

Volumn 20, Issue 3, 1997, Pages 374-380

  Quattrin, Teresa ^a,f   Thrailkill, Kathryn ^b   Baker, Lester ^c   Litton, Jean ^b   Dwigun, Karen ^a   Rearson, Melissa ^c   Poppenheimer, Mary ^d   Giltinan, David ^d   Gesundheit, Neil ^d,e   Martha Jr , Paul ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d GENENTECH INC   (United States)

^e Menlo Park and VIVUS   (United States)

^f CHILDREN S HOSPITAL OF BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; ISOPHANE INSULIN; PLACEBO; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SYNCOPE;

EID: 15644367198     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.3.374     Document Type: Article

References (47)

1. DCCT Research Group: Diabetes Control and Complications Trial (DCCT): the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Winter RJ, Phillips LS, Green OC, Traisman HS: Somatomedin activity in the Mauriac syndrome. J Pediatr 97:598-600, 1980
3. Wilson DM: Growth abnormalities in diabetes mellitus. In Contemporary Issues in Endocrinology and Metabolism. Vol. 4. Hintz RL, Rosenfeld RG, Eds. New York, Churchill Livingstone, 1987, p. 59-79
4. Nieves-Rivera F, Rogol AD, Veldhuis JD, Branscom DK, Martha PM Jr, Clarke WL: Alterations in growth hormone secretion and clearance in adolescent boys with insulin dependent diabetes mellitus. J Clin Endocrinol Metab 3:638-643, 1993
5. Hermansen K, Moller A, Christiansen CK, Christansen JS, Schmitz O, Orskov H, Albert KG, Mogensen CE: Diurnal plasma profiles of metabolite and hormone concentrations in insulin-dependent diabetic patients during conventional insulin treatment and continuous subcutaneous insulin infusion. Acta Endocrinol 114:433-439, 1987
6. Amiel SA, Sherwin RS, Hintz RL: Effect of diabetes and its control on insulin-like growth factors in the young subjects with type I diabetes. Diabetes 33:1175-1179, 1984
7. Blethen SL, Sargeant DT, Whitlow MG, Santiago JV: Effect of pubertal stage and recent blood glucose control on plasma somatomedin C in children with insulin-dependent diabetes mellitus. Diabetes 30:868-872, 1981
8. Sperling MA, Wollesen F, DeLamater PV: Daily production and metabolic clearance of growth hormone in juvenile diabetes mellitus. Diabetologia 9:380-383, 1973
9. Edge JA, Dunger DB, Matthews DR, Gilbert JP, Smith CP: Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab 71:1356-1361, 1990
10. Molnar GD, Taylor WE Langworthy A, Fatourechi V: Diurnal growth hormone and glucose abnormalities in unstable diabetics: studies of ambulatory-fed subjects during continuous blood glucose analysis. J Clin Endocrinol Metab 34:837-846, 1972
11. Johansen K, Hansen AP: Diurnal serum growth hormone levels in poorly and well-controlled juvenile diabetes. Diabetes 20:239-245, 1971
12. Shishko PI, Dreval AV Abugova IA, Zajarny IU, Goncharov VC: Insulin-like growth factors and binding proteins in patients with recent-onset type I (insulin dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res Clin Pract 25:1-12, 1994
13. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K: Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin dependent diabetes. J Clin Endocrinol Metab 79:872-878, 1994
14. Winter RJ, Phillips LS, Klein MN, Traisman HS, Green OC: Somatomedin activity and diabetic control in children with insulin-dependent diabetes. Diabetes 28:952-954, 1979
15. Hall K, Johansson BL, Povoa G, Thalme B: Serum levels of insulin-like growth factor (IGF) I, II and IGF binding protein in diabetic adolescents treated with continuous subcutaneous insulin infusion. J Intern Med 225:273-278, 1989
16. Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, Skarulis M: Clinical uses of insulin-like growth factor I. Ann Intern Med 120:593-601, 1994
17. Lanes R, Recker B, Fort P, Lifshitz F: Impaired somatomedin generation test in children with insulin-dependent diabetes mellitus. Diabetes 34:156-160, 1985
18. Press M, Tamborlane WV, Sherwin RS: Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes. N Engl J Med 310: 810-815, 1984
19. Defeo P, Perriello G, Ventura M: A growth hormone-induced hepatic insulin resistance, not an increase in plasma insulin clearance is the cause of the dawn phenomenon in type I (insulin dependent) diabetes (Abstract). Diabetologia 29:532a, 1986
20. Campbell PJ, Bolli GB, Cryer PE, Gerich JE: Pathogenesis of the dawn phenomenon in patients with insulin dependent diabetes mellitus: accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med 312:1473-1479, 1985
21. Campbell PJ, Bolli GB, Gerich JE: Prevention of the dawn phenomenon (early morning hyperglycemia) in insulin dependent diabetes mellitus by bedtime intranasal administration of long acting somatostatin analog. Metabolism 37:34-37, 1988
22. Arias P, Kerner W, Pfieffer EF: Suppression of the dawn phenomenon by somatostatin (Abstract). Diabetologia 27:252a, 1984
23. Davidson MB, Harris MD, Ziel FH, Rosenburg CS: Suppression of sleep-induced growth hormone secretion by anti-cholinergic agent abolishes dawn phenomenon. Diabetes 37:166-171, 1988
24. Sonksen PH, Russell-Jones D, Jones RH: Growth hormone and diabetes mellitus. Horm Res 40:68-79, 1993
25. Guler HP, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317:137-143, 1987
26. Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER: Recombinant human insulin-like growth factor (rhIGF I) reduces hyperglycemia in patients with extreme insulin resistance. Diabetologia 34:675-679, 1991
27. Zenobi PD, Jaeggi-Groisman SE, Riesne WF, Roder ME, Froesch ER: Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 90:2234-2241, 1992
28. Cheetham TD, Clayton KL, Taylor AM, Holly J, Matthews DR, Dunger DB: The effects of recombinant human insulin-like growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus. Clin Endocrinal 40:515-522, 1994
29. Cheetham TD, Jones J, Taylor AM, Hasley J, Matthews DR, Dunger DB: The effects of the recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type I diabetes mellitus. Diabetologia 36:678-681, 1993
30. Lieberman SA, Bukar J, Chen SA, Celniker AC, Compton PG, Cook J, Albu J, Perlman AJ, Hoffman AR: Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans. J Clin Endocrinol Metab 75:30-36, 1992
31. Quattrin T, Thrailkill KM, Baker L, Quarmby V, Compton P, Poppenheimer M, Martha P Jr.: Low plasma free IGF-I levels in IDDM: additional evidence for a bi-hormonal defect in diabetes (Abstract). Diabetes 45 (Suppl. 2):17A, 1996
32. Sherwin RS, Borg WP, Boulware SD: Metabolic effects of insulin-like growth factor I in normal humans (Review). Horm Res 41 (Suppl. 2):97-101, 1994
33. Takano K, Hizuka N, Asakawa K, Sukegawa I, Shizume K, Demura H: Effects of SC administration of recombinant human insulin-like growth factor I (IGF-I) on normal human subjects. Endocrinol Jpn 37:309-317, 1990
34. Guler HP, Schmid C, Zapf J, Froesch ER: Effects of insulin-like growth factor I in man. Acta Paediatr Scand 367 (Suppl.):52-54, 1990
35. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC: Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 129:2254-2265, 1991
36. Vlachopapadopoulou E, Zachwieja JJ, Gertner JM, Manzione D, Bier DM, Matthews DE, Slonim AE: Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy: a clinical research center study. J Clin Endocrinol Metab 12:3715-3723, 1995
37. Saad MF, Kades WW, Elsewafy WA, Ayad MF, Boyadjian R, Shapiro J: Low doses of insulin-like growth factor-I improve insulin sensitivity (Abstract). Diabetologia 37:40a, 1994
38. Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmano M, Froesh ER: Recombinant human insulin-like growth factor I (rhIGF-I) reduces hypoglycemia in patients with extreme insulin resistance. Diabetologia 34:675-679, 1991
39. Morrow L, O'Brien M, Moller D, Flier J, Moses A: Recombinant human IGF-I reverses hyperglycemia and improves insulin sensitivity in severe insulin resistance (Abstract). Diabetes 42 (Suppl.):269a, 1993
40. Kuzuya H, Matsbura N, Sakamoto M, Makino H, Sakamoto Y, Kudowaki T: Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42:696-705, 1993
41. Schalch DS, Turman NJ, Marcisin V, Guler HP: Short-term metabolic effects of recombinant human insulin-like growth factor I (rhIGF-I) in type II diabetes mellitus. In Modern Concepts of Insulin-Like Growth Factors. Spencer EM, Ed. New York, Elsevier, 1991, p. 705-715
42. Zenobi PD, Jaeggi-Grossman SE, Riesne WF, Roder ME, Froesch ER: Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 90:2234-2241, 1993
43. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons D: Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45:91-100, 1996
44. Yki-Iarvinen H, Koivisto VA: Natural course of insulin resistance in type I diabetes. N Engl J Med 315:224-230, 1986
45. Del Prato S, Nosadini R, Tiengo A, Tessari P, Avogaro A, Trevisan R, Valerio A, Muggeo C, Cobelli C, Toffolo G: Insulin-mediated glucose disposal in type I diabetes: evidence for insulin resistance. J Clin Endocrinol Metab 57:904-910, 1983
46. Kerr D, Tamborlane WV, Rife F, Sherwin R: Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans: a comparison with insulin. J Clin Invest 91:141-147, 1993
47. Boulware SD,Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS: Comparison of the metabolic effects of recombinant insulin-like growth factor I and insulin: dose response relationships in healthy young and middle aged adults. J Clin Invest 93:1131-1139, 1994